Abstract
The application of immunotherapy for the treatment of malignant diseases has attracted growing interest in recent years. Because T-cell immunity plays a major part in the control of tumor growth, strategies have been developed to specifically target and activate T-cells towards tumor cells by circumventing major histocompatibility complex (MHC)- restricted antigen recognition. Here we review the immunoreceptor (“T-body”) strategy based on grafting cytolytic T-cells with an antigen-specific, recombinant receptor with signalling properties. The extracellular domain of the receptor molecule consists of a single-chain antibody fragment (scFv) derived from a monoclonal antibody that binds to a tumor associated antigen. The intracellular domain is derived from a signalling receptor for cellular activation, e.g., the FcεRI receptor γ-chain or the CD3 σ-chain. Thereby, the immunoreceptor strategy combines the advantages of MHCindependent binding of antibodies to antigens with efficient T-cell activation. Due to the receptor design, T-cells grafted with immunoreceptors can be directed virtually against every cell defined by the particular antigen, including tumor cells and virally infected cells. This review summarizes the current knowledge about redirecting T-cell functions by grafting in recombinant immunoreceptors with specificity for tumor associated antigens and discusses the limitations and perspectives of the strategy for use in adoptive immunotherapy of malignant diseases.
Keywords: immunoreceptor, recombinant tcr, costimulation, tumor-specific t-cells, immunotherapy
Current Pharmaceutical Design
Title: Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Volume: 9 Issue: 24
Author(s): Hinrich Abken, Andreas Hombach and Claudia Heuser
Affiliation:
Keywords: immunoreceptor, recombinant tcr, costimulation, tumor-specific t-cells, immunotherapy
Abstract: The application of immunotherapy for the treatment of malignant diseases has attracted growing interest in recent years. Because T-cell immunity plays a major part in the control of tumor growth, strategies have been developed to specifically target and activate T-cells towards tumor cells by circumventing major histocompatibility complex (MHC)- restricted antigen recognition. Here we review the immunoreceptor (“T-body”) strategy based on grafting cytolytic T-cells with an antigen-specific, recombinant receptor with signalling properties. The extracellular domain of the receptor molecule consists of a single-chain antibody fragment (scFv) derived from a monoclonal antibody that binds to a tumor associated antigen. The intracellular domain is derived from a signalling receptor for cellular activation, e.g., the FcεRI receptor γ-chain or the CD3 σ-chain. Thereby, the immunoreceptor strategy combines the advantages of MHCindependent binding of antibodies to antigens with efficient T-cell activation. Due to the receptor design, T-cells grafted with immunoreceptors can be directed virtually against every cell defined by the particular antigen, including tumor cells and virally infected cells. This review summarizes the current knowledge about redirecting T-cell functions by grafting in recombinant immunoreceptors with specificity for tumor associated antigens and discusses the limitations and perspectives of the strategy for use in adoptive immunotherapy of malignant diseases.
Export Options
About this article
Cite this article as:
Abken Hinrich, Hombach Andreas and Heuser Claudia, Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454289
DOI https://dx.doi.org/10.2174/1381612033454289 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir
Current Cancer Drug Targets Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Applications and Toxicity of Silver Nanoparticles: A Recent Review
Current Topics in Medicinal Chemistry Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinases
Current Medicinal Chemistry Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells
Current Molecular Medicine Activities of Venom Proteins and Peptides with Possible Therapeutic Applications from Bees and WASPS
Protein & Peptide Letters Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention
Current Pharmaceutical Design Clomiphene Citrate, Metformin or Both for Ovulation Induction in Therapy Naïve Women with Polycystic Ovary Syndrome (PCOS)? A Descriptive Review
Current Drug Therapy Chemopreventive Properties of Indole-3-Carbinol, Diindolylmethane and Other Constituents of Cardamom Against Carcinogenesis
Recent Patents on Food, Nutrition & Agriculture Computational Analysis of Domains Vulnerable to HPV-16 E6 Oncoprotein and Corresponding Hot Spot Residues
Protein & Peptide Letters The Application of Proteomics in Neurology
Current Proteomics Gender Differences in Metabolic Syndrome – A Key Research Issue
Endocrine, Metabolic & Immune Disorders - Drug Targets The Cellular and Molecular Basis of Health Benefits of Grape Seed Proanthocyanidin Extract
Current Pharmaceutical Biotechnology The Antiproliferative Effect of Soy (<i>Glycine max</i>) Isoflavones Contained in a Nutraceutical on Cancer Cell Lines
Current Nutraceuticals